Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report
ObjectiveCurrent treatment agents for HCC are mostly immune checkpoint inhibitors (ICIs) plus bevacizumab and multitarget tyrosine kinase inhibitors (TKIs); however, their limited overall response rate and shorter median progression-free survival (PFS) discourage their frequent use. The development...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1130012/full |
| _version_ | 1827892803964764160 |
|---|---|
| author | Ningning Yan Ziheng Zhang Sanxing Guo Shujing Shen Xingya Li |
| author_facet | Ningning Yan Ziheng Zhang Sanxing Guo Shujing Shen Xingya Li |
| author_sort | Ningning Yan |
| collection | DOAJ |
| description | ObjectiveCurrent treatment agents for HCC are mostly immune checkpoint inhibitors (ICIs) plus bevacizumab and multitarget tyrosine kinase inhibitors (TKIs); however, their limited overall response rate and shorter median progression-free survival (PFS) discourage their frequent use. The development of Mesenchymal Epithelial Transition Factor receptor (MET) Tyrosine Kinase Inhibitors (MET-TKI) has transformed the treatment pattern in MET-altered solid tumors and improved their prognosis. However, the benefits of MET-TKIs in MET-amplified hepatocellular carcinoma (HCC) remain unclear.MethodsHere, we present a case of advanced HCC amplified with MET treated with savolitinib, a MET-TKI, after progression from first-line treatment with bevacizumab plus sintilimab.ResultsThe patient achieved a partial response (PR) to savolitinib in the second line setting. The progression-free survival (PFS) of first-line of bevacizumab plus sintilimab and sequential second-line treatment with MET-TKI, savolitinib, are 3 and over 8 months, respectively. furthermore, the patient still had continuous PR status with manageable toxicities.ConclusionsThe present case report provides first-hand evidence that savolitinib may be beneficial for patients with advanced MET-amplified HCC and offers a promising treatment option. |
| first_indexed | 2024-03-12T21:45:14Z |
| format | Article |
| id | doaj.art-5db4c7f40b514a51a937f58df7d10bbc |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-12T21:45:14Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-5db4c7f40b514a51a937f58df7d10bbc2023-07-26T12:05:11ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-05-011010.3389/fmed.2023.11300121130012Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case reportNingning Yan0Ziheng Zhang1Sanxing Guo2Shujing Shen3Xingya Li4Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaObjectiveCurrent treatment agents for HCC are mostly immune checkpoint inhibitors (ICIs) plus bevacizumab and multitarget tyrosine kinase inhibitors (TKIs); however, their limited overall response rate and shorter median progression-free survival (PFS) discourage their frequent use. The development of Mesenchymal Epithelial Transition Factor receptor (MET) Tyrosine Kinase Inhibitors (MET-TKI) has transformed the treatment pattern in MET-altered solid tumors and improved their prognosis. However, the benefits of MET-TKIs in MET-amplified hepatocellular carcinoma (HCC) remain unclear.MethodsHere, we present a case of advanced HCC amplified with MET treated with savolitinib, a MET-TKI, after progression from first-line treatment with bevacizumab plus sintilimab.ResultsThe patient achieved a partial response (PR) to savolitinib in the second line setting. The progression-free survival (PFS) of first-line of bevacizumab plus sintilimab and sequential second-line treatment with MET-TKI, savolitinib, are 3 and over 8 months, respectively. furthermore, the patient still had continuous PR status with manageable toxicities.ConclusionsThe present case report provides first-hand evidence that savolitinib may be beneficial for patients with advanced MET-amplified HCC and offers a promising treatment option.https://www.frontiersin.org/articles/10.3389/fmed.2023.1130012/fullliver cancertyrosine kinase inhibitorsMETsavolitinibMET-TKI |
| spellingShingle | Ningning Yan Ziheng Zhang Sanxing Guo Shujing Shen Xingya Li Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report Frontiers in Medicine liver cancer tyrosine kinase inhibitors MET savolitinib MET-TKI |
| title | Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report |
| title_full | Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report |
| title_fullStr | Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report |
| title_full_unstemmed | Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report |
| title_short | Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report |
| title_sort | advanced hcc with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib a case report |
| topic | liver cancer tyrosine kinase inhibitors MET savolitinib MET-TKI |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1130012/full |
| work_keys_str_mv | AT ningningyan advancedhccwithamplifiedmesenchymalepithelialtransitionfactorreceptorrespondswelltosavolitinibacasereport AT zihengzhang advancedhccwithamplifiedmesenchymalepithelialtransitionfactorreceptorrespondswelltosavolitinibacasereport AT sanxingguo advancedhccwithamplifiedmesenchymalepithelialtransitionfactorreceptorrespondswelltosavolitinibacasereport AT shujingshen advancedhccwithamplifiedmesenchymalepithelialtransitionfactorreceptorrespondswelltosavolitinibacasereport AT xingyali advancedhccwithamplifiedmesenchymalepithelialtransitionfactorreceptorrespondswelltosavolitinibacasereport |